| Not Yet Recruiting | IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed Relapsed/Refractory Follicular Lymphoma | Phase 3 | 2026-02-01 |
| Not Yet Recruiting | A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2025-10-15 |
| Recruiting | A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Healthy Postmenopausal Women | Phase 1 | 2025-08-18 |
| Recruiting | A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Atherosclerosis | EARLY_Phase 1 | 2025-03-10 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 NSCLC, TNBC | Phase 2 | 2024-12-01 |
| Recruiting | IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CM Chronic Myelomonocytic Leukemia | Phase 3 | 2024-11-11 |
| Recruiting | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors Advanced Solid Tumors, HCC | Phase 1 | 2024-07-23 |
| Not Yet Recruiting | A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgki Classic Hodgkin Lymphoma | Phase 3 | 2024-06-01 |
| Unknown | A Study Of IMM47 In Subjects With Advanced Solid Tumors Oncology | Phase 1 | 2023-08-18 |
| Unknown | A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2023-05-01 |
| Unknown | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 | 2023-03-23 |
| Unknown | IMM40H Phase I Dose Escalation and Expansion Tumor | Phase 1 | 2022-09-01 |
| Suspended | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing A Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer | Phase 1 | 2022-06-20 |
| Unknown | Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor Oncology, CTLA4 Haploinsufficiency | Phase 1 | 2022-06-15 |
| Unknown | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas Solid Tumor, Classic Hodgkin Lymphoma | Phase 1 / Phase 2 | 2022-05-17 |
| Unknown | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma | Phase 1 / Phase 2 | 2022-02-15 |
| Unknown | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrom Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2022-01-05 |
| Unknown | IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2021-08-18 |
| Suspended | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-H B-cell Non-Hodgkin's Lymphoma | Phase 1 | 2021-01-15 |
| Unknown | Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma CD20-positive B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2020-03-02 |
| Terminated | Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy Hematologic Malignancy | Phase 1 | 2019-11-19 |